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Thus far, two vitamin B-12-dependent enzymes have been identified in 
man [1]. One is the 5'-deoxyadenosylcobalamin-dependent methylmalonyl 
CoA mutase that catalyzes the conversion of L-methylmalonyl CoA to succinyl 
CoA. The other is the methylcobalamin-dependent NS-methyltetrahydrofolate -
homocysteine methyltransferase that, along with S-adenosylmethionine in a 
flavin-reducing system, catalyzes the conversion of homocysteine to methionine. 
Recently the methylcobalamin-dependent methyltransferase enzyme has been 
identified in extracts of normal human bone marrows [2] and in the bone 
marrow of patients with iron deficiency and leukemia [2]. In two cases of 
vitamin B-12 deficiency, the enzyme was found to exist primarily in the form 
of the apoenzyme [2]. In the present studies, attention was focused on patients 
with several types of disorders of erythropoiesis characterized by marked 
erythroid hyperplasia of the bone marrow, in an effort to detect differences 
in the methyltransferase activity of the marrow extracts obtained from these 
individuals. 
Bone marrow was obtained by needle aspiration from the sternum or 
iliac crest at the time of diagnosis from two patients with severe untreated 
autoimmune hemolytic anemia; five patients with chronic erythremic myelosis 
(DiGuglielmo syndrome), a refractory macrocytic anemia that may be the fore- 
runner of acute leukemia in certain individuals [3--5] ; and from two patients 
with severe untreated pernicious anemia. According to stringent human sub- 
ject regulations, the marrows were aspirated by the "second-pull" technique 
following the initial diagnostic aspirate, thereby permitting only small quan- 
tities of marrow to be obtained (10--20 mg). Similar ethical limitations did 
not permit the obtaining of bone marrow from normal, healthy individuals 
at the time of this study. Consequently, only pathological marrows character- 
ized by marked erythroid hyperplasia were utilized. Because of the necessity 
of utilizing marrow extracts rich in protein for the enzymatic assay [2], only 
duplicate assays of the methyltransferase could be performed in the present 
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experiments, and various additives as described later could not be tested as a 
result of these limitations. The particles of marrow were washed five times in 
iced Hank's solution (BBL, Cockeysville, Md.), and homogenized in 1.0--1.5 
ml iced 0.34 M sucrose solution for 45 min. The homogenate was dialyzed 
overnight at 4°C in 1.5 M potassium phosphate buffer and protein determined 
by the method of Lowry et al. [6]. 
The procedure for determination of the 5-methyltetrahydrofolate- 
dependent methyltransferase was essentially that described by Loughlin et al. 
[ 7 ]. Reagents included N s- [ 14 C] methyltetrahydrofolic acid (61.1 Ci/mol, 
Amersham Searle), NS-methyltetrahydrofolic acid, homocysteine [8], FADH2 
[ 7 ], and S-adenosylmethionine. The latter four reagents were obtained from 
Sigma Chemical Co., St. Louis, and prepared freshly each time. Homogenate 
preparations from the patient's marrows were used as the source of the 
methyltransferase enzyme in an assay system with a final volume of 1.0 ml 
containing 0.1 ~mol potassium phosphate buffer pH 7.2, NS-[14C]methyl- 
tetrahydrofolic acid 0.528 pmol (20 Ci/mol), 10 pmol homocysteine, 1.0 
pmol S-adenosylmethionine, 0.2 pmol FADH2, 0.3 ml of the marrow 
homogenate and 0.1 ml distilled water. Assay mixtures were incubated for 
2 h at 37°C in a hydrogen atmosphere and the reaction was terminated by 
immersion of the reaction tubes in an ice bath. Control tubes were run for 
each experiment, and included omission of essential reactants, such as homo- 
genate and S-adenosylmethionine and other types of temperature controls as 
described by Loughlin et al. [7]. Following termination of the reaction, 
residual labelled and unlabelled methyltetrahydrofolate were removed from 
the assay mixture by passage of this mixture through a microcolumn 
(0.5 × 4.0 cm) of Dowex-1 chloride [9]. The eluates from experimental and 
control samples were lyophilized and stored at --20°C. NS-[14C]methyltetra - 
hydrofolate and [~4C] methionine were separated in an descending paper 
chromatography system containing isopropanol/water/1 M HC1 (160:40:8, 
v/v/v). Known standards of methionine (Sigma} were used in each chromatogram. 
Amino acid spots were identified with ninhydrin/hydridantin reagent [ 10] cut 
from the paper chromatograms, placed in scintillation vials containing Toluene/ 
Triton X-100/PPO/POPOP and counted in a Nuclear Chicago model 725 liquid 
scintillation counter. 
Since all of the control samples contained only background radioactivity 
at the site of methionine, the activity of the 5-methyltetrahydrofolate methyl- 
transferase was expressed as the difference between measured radioactivity of 
the [~4C] methionine spot of the incubation mixture containing all of the 
reactants, minus the background radioactivity seen in the methionine area in 
all of the controls, divided by the total protein of the homogenate. Enzymatic 
activity was expressed as pmol p4C] methionine/mg protein/h. 
Table I illustrates the results of the assays experiments. In the various 
disorders of erythropoiesis studied, the two patients with autoimmune 
hemolytic anemia had the highest values. In the five cases of chronic erythremic 
myelosis, methyltransferase activity was unusually low compared to those in 
the cases of autoimmune hemolytic anemia, and in one patient with chronic 
erythremic myelosis, no methyltransferase activity could be ascertained. In the 
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T A B L E  I 
5 " M E T H Y L T E T R A H Y D R O F O L A T E - D E P E N D E N T  M E T H Y L T R A N S F E R A S E  A C T I V I T Y  IN DIS- 
O R D E R S  OF E R Y T H R O P O I E S I S  C H A R A C T E R I Z E D  BY M A R R O W  E R Y T H R O I D  H Y P E R P L A S I A  
Disorder Patient [ 14 C ] Methionine 
( p m o l / m g  protein/h) 
A u t o i m m u n e  h e m o l y t i c  a n e m i a  
Chron ic  e r y t h r e m i c  myelos i s  
Untreated pern ic ious  a n e m i a  
1 258  
2 152  







two patients with severe untreated pernicious anemia and in all of the control 
samples, including those where various essential reactants were omitted, 
methyltransferase activity could not be detected. 
The present studies have examined 5-methyltetrahydrofolate-homocysteine 
methyltransferase activity in marrow extracts from patients with erythroid 
disorders typified by marrow erythroid hyperplasia. Evidence for defective 
methionine generation was obtained in the cases of vitamin B-12 deficiency, 
as noted by others [2,11]. In addition, unusually low values for methyltrans- 
ferase were found in patients with chronic erythremic myelosis (DiGuglielmo 
syndrome), a disorder often regarded as a preleukemic condition [3--5] and 
associated with other enzymatic abnormalities [12--14]. 
Although in all instances lower than in the two cases of autoimmune 
hemolytic anemia, variations in the enzymatic activity of patients with chronic 
erythremic myelosis are difficult to explain at this point. One individual 
(Patient 4) whose methylcobalamin methyltransferase activity was 21 pmol/mg 
protein/h subsequently developed subacute myelomonocytic leukemia [15] 
approximately a year after the diagnosis of chronic erythremic myelosis was 
made. Up to the time of leukemic transformation, the clinical course and 
severity of disease in this patient was identical to the other patients with 
chronic erythremic myelosis. Patient 7, whose bone marrow did not demon- 
strate detectable methylcobalamin methyltransferase activity, has not as yet 
shown evidence of leukemic transformation, although he has had an estab- 
lished diagnosis of chronic erythremic myelosis for 5 years and in all hema- 
tologic and clinical respects resembles the other patients with this disorder. 
Therefore, it is not possible at this point to predict which patients may have 
a greater likelihood of ultimately developing acute myeloblastic or myelo- 
monocytic leukemia on the basis of certain methylcobalamin methyltrans- 
ferase values of their marrow erythroid precursors. Studies of additional 
patients with chronic erythremic myelosis combined with prolonged observa- 
tions of these patients may permit such correlations to be made in the future. 
Because of the small amounts of marrow available, and the necessity of 
utilizing maximal amounts of marrow protein to perform methyltransferase 
assays, in the present experiments we were unable to explore some of the 
reasons why the methyltransferase activity was low in chronic erythremic 
myelosis, including the possibilities of abnormalities of the apoenzyme or 
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the presence of  a metabolic inhibitor. When sufficient quantities of  marrow 
become available, it will be important to perform the methyltransferase 
assays in the presence of  methylcobalamin and to mix the chronic erythremic 
myelosis marrow extracts with normal marrow extracts prior to methyltrans- 
ferase assays, to gain further information regarding some of  the mechanisms 
that might be responsible for the results obtained in the present study. 
Supported by the National Cancer Institute Grant USPHS CA 14428-03 
and the Loyal V. Reynolds Memorial grant for cancer research of  the American 
Cancer Society PDT-13A. 
References 
1 Gunz, F, and Baikie, A.G. (1974) Leukemia  3rd Edn., Grime and Strat ton,  New York. 
2 Bessis, M. (1973) Living Blood Cells and their Ultrastructttre, Springer, New York. 
3 Kass, L. and Schnitzer, B. (1975) Refractory Anemia, Thomas, Springfield. 
4 Lowry,  O.H., Rosebrough, J.J., Far£, A.L. and Randall,  R.J. (1951) J. Biol. Chem. 193, 265 
5 Lov_~hlln, R.E., Elford, H.L. and Buchanan, J.M. (1964) J. Biol. Chem. 239, 2888. 
6 Hatch, F.T., Larrabbee, A.R., Cathou, R.E. and Buchanan, J.M. (1961) J. Biol. Chem. 236, 1095. 
7 Weissbach, H., Peterkofsky,  A., Redfleld, B.G. and Dickerman, H. (1963) J. Biol. Chem. 238, 3319. 
8 Moore, S. and Stein, W.H. (1954) J. Biol. Chem. 211, 907. 
9 Dickerman, H., Redfleld, B.G., Bieri, J.G. and Weissbaeh, H. (1964) J. Biol. Chem. 239, 2545. 
10 Taylor, R.T., Hanna, M.L. and Hutton,  J.J. (1974) Arch. Biochem. Biophys. 165, 787. 
11 Steiner, J., Baldini, M. and Dameshek, W. (1963) Blood 22, 810. 
12 Bessis, M., Dreyfus, B., Breton-Gorius, J. and Sultan, C. (1969) Nouv. Rev. Ft. Hematol.  9, 87. 
13 Valentine, W.N., Konrad, P.N. and Paglia, D.E. (1973) Blood 41, 857. 
14 Kass, L. (1973)  PrOc. Soc. Exp. Biol. Med. 144, 887. 
15 Kass, L. (1974) Proc. Soc. Exp. Biol. Med. 145, 944. 
